U.S. approves new drug from GSK for myelofibrosis patients with anemia

GSK gained the medicine through last year’s $1.9 billion acquisition of US biotech Sierra Oncology .

The medicine, momelotinib, is likely to garner sales “comfortably” above $1 billion a year.

GSK has worked to rebuild its oncology pipeline after it sold off its cancer drugs portfolio to Novartis in 2015 .